Xilio Therapeutics Inc (XLO) Stock Price, Quote & News

Company Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 524 2466

Website: xiliotx.com

Address:

828 Winter Street, Suite 300, Waltham, United States

biohuntress Jun. 19 at 1:43 AM

$XLO I think some consolidation before trying to punch through the 200d again would be helpful

0 · Reply

Stellar2X Jun. 18 at 10:28 PM

$XLO $MXC $NYC.X $HCAI seen

0 · Reply

Stellar2X Jun. 18 at 8:30 PM

$TVGN $FUBO $TC $XLO flame

0 · Reply

LabPsycho Jun. 18 at 7:36 PM

$XLO Over $9 as predicted below and in the time frame. I give myself a Grade of "A".

0 · Reply

biohuntress Jun. 18 at 5:07 PM

$XLO post R/S prices warrants 0.75/10.50 employee options 1.00/14.00 execs 1.50/21.00

0 · Reply

LabPsycho Jun. 18 at 4:59 PM

$XLO @biohuntress That is what it looked like...700 shares knocked it down 93 cents. I think XLO percolating and going to move soon. Over $9 today is my prediction.

0 · Reply

biohuntress Jun. 18 at 4:38 PM

$XLO 11.5k shares traded at 7.82 on that dip....hope it was stop hunt before a move up

1 · Reply

ezimon Jun. 18 at 9:06 AM

$XLO this thing has nothing but drop for over one year that I have been watching it. its Avg. Vol recently has been nothing. All of a sudden without any news volume goes up and so does its price. Very suspicious, most likely some sort of fund exit cash pump? Maybe trying to get it to $10.50 (about what they paid for warrants) and get out or some options for the management team? I could be wrong but I have zero trust in this company`s management team.

1 · Reply

ezimon Jun. 18 at 8:56 AM

$XLO 🤣

0 · Reply

LabPsycho Jun. 17 at 8:43 PM

$XLO Is moving closer to the upside ($12.4) than the downside ($4.5) buy / add price per whimsical investment thesis posted below. Good luck.

1 · Reply

Xilio Therapeutics Registration statement: Registration filing

2026-05-12T16:42:54.000Z - 5 weeks ago

Xilio Therapeutics files $250M mixed securities shelf

May 12, 2026, 8:00 AM EDT - 5 weeks ago

Xilio Therapeutics Registration statement: Registration filing

May 12, 2026, 7:30 AM EDT - 5 weeks ago

Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates

May 12, 2026, 7:30 AM EDT - 5 weeks ago

Xilio Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:30 AM EDT - 5 weeks ago

Xilio Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 6 weeks ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 28, 2026, 8:00 AM EDT - 7 weeks ago

Xilio Therapeutics Proxy statement: Proxy filing

2026-04-17T20:20:14.000Z - 2 months ago

Xilio announces new preclinical data for XTX601 at AACR

Apr 17, 2026, 4:01 PM EDT - 2 months ago

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

2026-04-16T11:40:39.000Z - 2 months ago

Xilio Therapeutics appoints Blanchard to its Board of Directors

Apr 16, 2026, 7:30 AM EDT - 2 months ago

Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Xilio Therapeutics Annual report: Q4 2025

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Xilio Therapeutics Earnings release: Q4 2025

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Xilio Therapeutics Annual report: Q4 2025

Mar 17, 2026, 4:45 PM EDT - 3 months ago

Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

2026-03-13T23:52:06.000Z - 3 months ago

Xilio Therapeutics Inc trading halted, news pending

2026-03-12T12:45:03.000Z - 3 months ago

Xilio Therapeutics announces 1-for-14 reverse stock split

Mar 12, 2026, 8:30 AM EDT - 3 months ago

Xilio Therapeutics Announces 1-for-14 Reverse Stock Split

Mar 9, 2026, 3:00 PM EDT - 3 months ago

Xilio Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 8:00 AM EST - 3 months ago

Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Feb 11, 2026, 9:34 PM EST - 4 months ago

Xilio Therapeutics Announces Pricing of Underwritten Offering

Jan 26, 2026, 7:00 AM EST - 5 months ago

Xilio Therapeutics Proxy statement: Proxy Filing

Jan 16, 2026, 7:00 AM EST - 5 months ago

Xilio Therapeutics Proxy statement: Proxy Filing

2026-01-08T13:50:16.000Z - 5 months ago

Xilio Therapeutics highlights upcoming milestones, corporate updates

Jan 8, 2026, 8:30 AM EST - 5 months ago

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Nov 13, 2025, 4:00 PM EST - 7 months ago

Xilio Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 4:00 PM EST - 7 months ago

Xilio Therapeutics Quarterly report: Q3 2025

2025-11-13T12:42:01.000Z - 7 months ago

Xilio Therapeutics expects cash to fund operations into Q1 of 2027

2025-11-13T12:35:19.000Z - 7 months ago

Xilio Therapeutics reports Q3 EPS (11c) vs (22c) last year

Nov 13, 2025, 7:30 AM EST - 7 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Nov 10, 2025, 4:30 PM EST - 7 months ago

Xilio Therapeutics Transcript: Status Update

Nov 10, 2025, 4:30 PM EST - 7 months ago

Xilio Therapeutics Press release: Status Update

Nov 10, 2025, 4:30 PM EST - 7 months ago

Xilio Therapeutics Slides: Status Update

2025-11-07T14:21:23.000Z - 7 months ago

Xilio Therapeutics presents new data across portfolio at SITC

2025-11-07T14:20:51.000Z - 7 months ago

Xilio Therapeutics announces new data on Phase 2 trial of vilastobart

Nov 7, 2025, 9:05 AM EST - 7 months ago

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Nov 7, 2025, 9:01 AM EST - 7 months ago

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Oct 30, 2025, 9:01 AM EDT - 8 months ago

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

Oct 20, 2025, 8:00 AM EDT - 8 months ago

Xilio Therapeutics Proxy statement: Proxy Filing

Oct 10, 2025, 8:00 AM EDT - 8 months ago

Xilio Therapeutics Proxy statement: Proxy Filing

Oct 3, 2025, 9:00 AM EDT - 9 months ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

2025-09-09T11:35:21.000Z - 10 months ago

Xilio Therapeutics announces initiation of Phase 2 trial for efarindodekin alfa

GILD

2025-09-09T11:35:08.000Z - 10 months ago

Xilio Therapeutics sees cash runway into 1Q27

Sep 9, 2025, 7:30 AM EDT - 10 months ago

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

2025-08-14T11:35:14.000Z - 11 months ago

Xilio Therapeutics reports Q2 EPS (16c) vs (24c) last year

Aug 14, 2025, 7:30 AM EDT - 11 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

Aug 14, 2025, 7:30 AM EDT - 11 months ago

Xilio Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 11 months ago

Xilio Therapeutics Earnings release: Q2 2025

2025-08-06T10:32:01.000Z - 11 months ago

Xilio Therapeutics initiated with an Outperform at Leerink

Jul 2, 2025, 4:30 PM EDT - 1 year ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 10, 2025, 4:30 PM EDT - 1 year ago

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

Jun 5, 2025, 6:38 PM EDT - 1 year ago

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Xilio Therapeutics Slides: Corporate Presentation

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Proxy statement: Proxy Filing

2025-06-02T12:55:18.000Z - 1 year ago

Xilio Therapeutics announces pricing of $50M public offering

Jun 2, 2025, 8:46 AM EDT - 1 year ago

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

2025-06-02T10:20:44.000Z - 1 year ago

Xilio Therapeutics announces offering of warrants, no amount given

Jun 2, 2025, 6:11 AM EDT - 1 year ago

Xilio Therapeutics Announces Proposed Public Offering

2025-06-01T20:25:03.000Z - 1 year ago

Xilio Therapeutics announces updated Phase 2 data for vilastobart

May 31, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 8, 2025, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 7, 2025, 6:00 PM EDT - 1 year ago

Xilio Therapeutics Earnings release: Q1 2025

May 7, 2025, 6:00 PM EDT - 1 year ago

Xilio Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Registration statement: Registration Filing

May 2, 2025, 4:30 PM EDT - 1 year ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Proxy statement: Proxy Filing

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Xilio Therapeutics Registration statement: Registration Filing

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Earnings release: Q4 2024

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Annual report: Q4 2024

Mar 3, 2025, 9:50 AM EST - 1 year ago

Xilio Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 4:30 PM EST - 1 year ago

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 8:30 AM EST - 1 year ago

Xilio Therapeutics Transcript: Study Update

Feb 12, 2025, 8:30 AM EST - 1 year ago

Xilio Therapeutics Press release: Study Update

Feb 12, 2025, 8:30 AM EST - 1 year ago

Xilio Therapeutics Slides: Study Update

Feb 12, 2025, 7:35 AM EST - 1 year ago

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Feb 12, 2025, 7:33 AM EST - 1 year ago

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Jan 22, 2025, 8:30 AM EST - 1 year ago

Xilio Therapeutics Transcript: Study Update

Jan 22, 2025, 8:30 AM EST - 1 year ago

Xilio Therapeutics Press release: Study Update

Jan 21, 2025, 5:05 PM EST - 1 year ago

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Jan 17, 2025, 4:30 PM EST - 1 year ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 19, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Dec 16, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Nov 7, 2024, 4:30 PM EST - 1 year ago

Xilio Therapeutics Transcript: Study Update

Nov 7, 2024, 4:30 PM EST - 1 year ago

Xilio Therapeutics Press release: Study Update

Nov 7, 2024, 4:30 PM EST - 1 year ago

Xilio Therapeutics Slides: Study Update

Nov 7, 2024, 9:15 AM EST - 1 year ago

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Nov 7, 2024, 9:05 AM EST - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Nov 7, 2024, 9:00 AM EST - 1 year ago

Xilio Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 9:00 AM EST - 1 year ago

Xilio Therapeutics Earnings release: Q3 2024

Oct 30, 2024, 9:01 AM EDT - 1 year ago

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 1 year ago

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Xilio Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Aug 8, 2024, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Earnings release: Q2 2024

Jun 13, 2024, 4:05 PM EDT - 2 years ago

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.

May 14, 2024, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

May 14, 2024, 7:00 AM EDT - 2 years ago

Xilio Therapeutics Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Xilio Therapeutics Earnings release: Q1 2024

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Xilio Therapeutics Registration statement: Registration Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Xilio Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Xilio Therapeutics Proxy statement: Proxy Filing

Apr 1, 2024, 4:05 PM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Apr 1, 2024, 4:00 PM EDT - 2 years ago

Xilio Therapeutics Annual report: Q4 2023

Apr 1, 2024, 4:00 PM EDT - 2 years ago

Xilio Therapeutics Earnings release: Q4 2023

Mar 28, 2024, 7:05 AM EDT - 2 years ago

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GILD

Mar 4, 2024, 10:30 AM EST - 2 years ago

Xilio Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 28, 2024, 4:01 PM EST - 2 years ago

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Feb 7, 2024, 12:30 PM EST - 2 years ago

Xilio Therapeutics Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 31, 2024, 4:01 PM EST - 2 years ago

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 8, 2024, 7:30 AM EST - 2 years ago

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Jan 8, 2024, 7:00 AM EST - 2 years ago

Xilio Therapeutics Slides: Corporate Presentation

Dec 7, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Nov 9, 2023, 4:01 PM EST - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

biohuntress Jun. 19 at 1:43 AM

$XLO I think some consolidation before trying to punch through the 200d again would be helpful

0 · Reply

Stellar2X Jun. 18 at 10:28 PM

$XLO $MXC $NYC.X $HCAI seen

0 · Reply

Stellar2X Jun. 18 at 8:30 PM

$TVGN $FUBO $TC $XLO flame

0 · Reply

LabPsycho Jun. 18 at 7:36 PM

$XLO Over $9 as predicted below and in the time frame. I give myself a Grade of "A".

0 · Reply

biohuntress Jun. 18 at 5:07 PM

$XLO post R/S prices warrants 0.75/10.50 employee options 1.00/14.00 execs 1.50/21.00

0 · Reply

LabPsycho Jun. 18 at 4:59 PM

$XLO @biohuntress That is what it looked like...700 shares knocked it down 93 cents. I think XLO percolating and going to move soon. Over $9 today is my prediction.

0 · Reply

biohuntress Jun. 18 at 4:38 PM

$XLO 11.5k shares traded at 7.82 on that dip....hope it was stop hunt before a move up

1 · Reply

ezimon Jun. 18 at 9:06 AM

1 · Reply

ezimon Jun. 18 at 8:56 AM

$XLO 🤣

0 · Reply

LabPsycho Jun. 17 at 8:43 PM

$XLO Is moving closer to the upside ($12.4) than the downside ($4.5) buy / add price per whimsical investment thesis posted below. Good luck.

1 · Reply

Jtlo Jun. 17 at 7:55 PM

$XLO is the pump near?

0 · Reply

LabPsycho Jun. 17 at 5:13 PM

$XLO 45k shares traded so far today makes 2 recent days now volume as been 3-4X normal. This better start floating up or its going down. Good luck

1 · Reply

LabPsycho Jun. 16 at 1:06 PM

$XLO @809trader Yes, if you or any other posters here want to / can do a bit more homework on those biotechs that R/S then 2-4X within a year and post your findings that would be helpful. I am doing the list from vague memory... One thing in common, they were all trading below cash. Also, I do think GILD was invested in a couple at some point..maybe not on my list ASBM? LPTX ? (changed to a crypto ticker) @CagedMoney

0 · Reply

LabPsycho Jun. 15 at 6:17 PM

$XLO Tiny bit more volume coming in...seems like should start to (finally!) drift up.

0 · Reply

Hazysixty6 Jun. 13 at 1:03 AM

$XLO Have held onto this for over a year now. Just about ready to break even. Hoping to do more than that but at this point I could do more with the money than they have in a shorter period of time. I can’t help but be bullish but it is with a high degree of skepticism!

1 · Reply

LabPsycho Jun. 12 at 3:54 PM

$XLO @CagedMoney The 'violent' move as you say, typically occurs 4-8 months after the reverse split IMO. Some biotech examples may include: ASMB SNSE MRSN STRO (there are at least 2 more but I can not recall)

1 · Reply

LabPsycho Jun. 12 at 3:50 PM

$XLO @8_seconds Lol...i guess just @809trader single handedly holding this up 🤷‍♀️

1 · Reply

CagedMoney Jun. 11 at 8:49 PM

$XLO This will be a violent move when it does happen 🤫

0 · Reply

8_seconds Jun. 9 at 7:55 PM

$XLO well tickle me Pink, this stock is one huge pile of 💩

0 · Reply

biohuntress Jun. 9 at 3:36 PM

$XLO Hello? Is there anybody in there? Just nod if you can hear me Is there anyone home?

1 · Reply

ezimon Jun. 9 at 3:09 PM

$XLO doubt it

1 · Reply

809trader Jun. 9 at 12:42 PM

$XLO if this company is not bought in the next 9 month I’ll be shock and will probably sell my big position. Buyout will happen 😎🥳😎🥳

0 · Reply

Market Cap	57.53M
Revenue (ttm)	43.77M
Net Income (ttm)	-35.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-80.05%
Debt to Equity Ratio	0.00

Volume	56,700
Avg Vol	44,816
Day's Range	N/A - N/A
Shares Out	6.58M
Stochastic %K	74%
Beta	-0.12
Analysts	Sell
Price Target	$20.00